|
EMA Finalizes Guidance on Drug Marketing Authorization Renewals
Drug companies will have to submit updated safety and efficacy data, as well as an updated analysis of a drug’s risks and benefits when renewing marketing authorizations in the EU, according to an European Medicines Agency (EMA) final guideline on processing renewal applications.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives